1. Anti-infection
  2. HBV

Telbivudine (Synonyms: Epavudine; L-Thymidine; NV 02B)

Cat. No.: HY-B0017 Purity: 99.52%
Data Sheet SDS Handling Instructions

Telbivudine, a specific inhibitor of hepatitis B virus (HBV) replication, is an antiviral drug used in the treatment of hepatitis B infection.

For research use only. We do not sell to patients.
Telbivudine Chemical Structure

Telbivudine Chemical Structure

CAS No. : 3424-98-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $77 In-stock
10 mg $70 In-stock
50 mg $210 In-stock
100 mg $256 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Telbivudine, a specific inhibitor of hepatitis B virus (HBV) replication, is an antiviral drug used in the treatment of hepatitis B infection. Target: HBV Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. Telbivudine is a synthetic thymidine nucleoside analogue, it is the L-isomer of thymidine. It is taken once daily. Telbivudine is a potent antiviral that provides effective and sustained viral suppression in patients with compensated CHB. In clinical trials, treatment outcomes were improved significantly more with telbivudine 600 mg once daily than with lamivudine 100 mg or adefovir 10 mg once daily, and telbivudine-treated patients had significantly less viral resistance than lamivudine-treated patients. Telbivudine is associated with a medium genetic barrier to resistance and, as patients with undetectable HBV DNA levels have significantly improved outcomes, it is recommended that HBV DNA levels are monitored at week 24 (and 6 monthly thereafter), with the addition of a nucleoside/nucleotide analogue without cross resistance (such as adefovir dipivoxil) if viraemia is present to reduce the risk of resistance (Roadmap concept). Telbivudine was generally well tolerated in clinical trials for periods of up to 4 years, and has a similar tolerability profile to that of lamivudine.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01065818 Columbia University|National Cancer Institute (NCI) Esophageal Cancer August 2009
NCT00236275 Assistance Publique - Hôpitaux de Paris|Pierre and Marie Curie University Breast Cancer May 2004 Phase 3
NCT01047059 University of Cologne Non-Small-Cell Lung Carcinoma January 2010 Phase 2
NCT00939068 Southeast University, China Chronic Hepatitis B, Gestation February 2008 Phase 4
NCT01380951 The Fifth People's Hospital of Suzhou Liver Cirrhosis|Chronic Hepatitis B May 2011 Phase 4
NCT02058108 Novartis Pharmaceuticals|Novartis Chronic Hepatitis B October 31, 2014 Phase 3
NCT00646503 Novartis Hepatitis B, Chronic March 2008 Phase 4
NCT01379508 Novartis Pharmaceuticals|Novartis Chronic Hepatitis B March 2011 Phase 4
NCT00142298 Novartis Pharmaceuticals|Merck Sharp & Dohme Corp.|Novartis Chronic Hepatitis B March 2005 Phase 3
NCT01637844 Yi-Hua Zhou|Taixing People's Hospital|Fourth People's Hospital of Zhenjiang, China|Wuxi Maternal and Child Health Hospital|Kunshan First People Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School HBV April 2012 Phase 4
NCT02894554 National Taiwan University Hospital HBsAg-positive Renal Allograft Recipients July 2014 Phase 4
NCT01260610 Institute of Liver and Biliary Sciences, India Chronic Hepatitis B June 2011
NCT01595685 Asan Medical Center Chronic Viral Hepatitis B Without Delta-agent May 2012 Phase 3
NCT00467545 Novartis Pharmaceuticals|Novartis Chronic Hepatitis B April 2007 Phase 4
NCT01743079 Beijing YouAn Hospital|New Discovery LLC Chronic Hepatitis B|Late Pregnancy|Transmission|Complication January 2009 Phase 4
NCT02447705 Chang Gung Memorial Hospital Disorder Related to Transplantation|Virus Diseases|Injury Due to Exposure to External Cause June 2013 Phase 2|Phase 3
NCT00970216 Chang Gung Memorial Hospital Chronic Hepatitis B February 2009
NCT00076336 Novartis Pharmaceuticals|Novartis Hepatitis|Hepatitis B, Chronic|Cirrhosis December 2003 Phase 3
NCT00412750 Novartis Hepatitis B December 2006 Phase 3
NCT02049736 Chinese University of Hong Kong Chronic Hepatitis B December 2013
NCT00537537 Novartis Pharmaceuticals|Novartis Hepatitis B, Chronic August 2007 Phase 4
NCT01804387 Korea University Chronic Hepatitis B May 2011 Phase 4
NCT02774837 Seng Gee Lim|National Medical Research Council (NMRC), Singapore|Singapore Clinical Research Institute|National University Health System, Singapore Chronic Hepatitis B May 2016 Phase 4
NCT00962533 Nanfang Hospital of Southern Medical University|Major Science and Technology Special Project of China Eleventh Five-year|Novartis Hepatitis B, Chronic August 2009 Phase 4
NCT01337791 Southeast University, China Chronic Hepatitis B|Pregnancy Complications|High Viral Load|Elevated Alanine Aminotransferase Levels August 2008 Phase 4
NCT00907894 Novartis Pharmaceuticals|Novartis Chronic Hepatitis B February 2009 Phase 1
NCT00412529 Novartis Pharmaceuticals|Novartis Hepatitis B|Chronic Hepatitis B December 2006 Phase 3
NCT01521975 Third Affiliated Hospital, Sun Yat-Sen University|Guangdong Provincial People's Hospital|Guangzhou 8th People's Hospital Hepatitis B, Chronic September 2011 Phase 4
NCT01588912 Pusan National University Yangsan Hospital Chronic Hepatitis B April 2012 Phase 4
NCT00640588 Novartis Pharmaceuticals|Novartis Hepatitis B, Chronic March 2008 Phase 3
NCT01799486 Lin Bingliang|Novartis|Sun Yat-sen University HBV-related Liver Cirrhosis February 2013 Phase 4
NCT01005238 University Hospital, Basel, Switzerland Hepatitis, Chronic September 2009 Phase 4
NCT00805675 Novartis Pharmaceuticals|Novartis Hepatitis B Virus November 2008 Phase 3
NCT00781105 Novartis Pharmaceuticals|Novartis Chronic Hepatitis B August 1, 2008 Phase 4
NCT00606099 Novartis Chronic Hepatitis B November 2007 Phase 4
NCT01693679 Shao-quan Zhang|Sun Yat-sen University HBV-related Liver Cirrhosis September 2012 Phase 4
NCT01270165 Yonsei University Chronic Hepatitis B June 2010 Phase 3
NCT00877149 Novartis Pharmaceuticals|Novartis Compensated Chronic Hepatitis B March 2009 Phase 4
NCT00057265 Novartis|Novartis Pharmaceuticals Chronic Hepatitis B February 2003 Phase 3
NCT00710216 University of Ulm|Novartis Hepatitis B, Chronic Phase 4
NCT00131742 Novartis|Novartis Pharmaceuticals Chronic Hepatitis B July 2004 Phase 3
NCT00132652 Novartis|Novartis Pharmaceuticals Chronic Hepatitis B February 2005 Phase 3
NCT00804622 The University of Hong Kong|Novartis Pharmaceuticals Chronic Hepatitis B December 2008 Phase 2
NCT00124241 Novartis|Novartis Pharmaceuticals Hepatitis B Phase 2
NCT00862706 Novartis Pharmaceuticals|Novartis Compensated Chronic Hepatitis B April 2009 Phase 4
NCT00115245 Novartis|Novartis Pharmaceuticals Chronic Hepatitis B November 2004 Phase 3
NCT00128544 Novartis|Novartis Pharmaceuticals Hepatitis B May 2005 Phase 2
NCT00275652 Mayo Clinic|Merck Sharp & Dohme Corp. Hepatitis B|Cirrhosis June 2004 Phase 3
NCT00409019 Novartis Pharmaceuticals|Novartis Chronic Hepatitis B Phase 4
NCT02338674 Fuzhou General Hospital Hepatitis B, Chronic October 2014 Phase 1|Phase 2
NCT01732224 Institute of Liver and Biliary Sciences, India Spontaneous Reactivation of Hepatitis B November 2012
NCT02826070 Nanfang Hospital of Southern Medical University|Major Science and Technology Special Project of China Twelfth-Five-Year Project|Novartis Hepatitis B, Chronic April 2015 Phase 4
NCT00376259 Novartis Hepatitis B January 2007 Phase 3
NCT01529255 Nanfang Hospital of Southern Medical University|Major Science and Technology Special Project of China Eleventh Five-year|Novartis Hepatitis B, Chronic August 2011 Phase 4
NCT00051090 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Hepatitis B
NCT01102335 Fudan University Hepatocellular Carcinoma April 2010 Phase 4
NCT02253485 Beijing Ditan Hospital Immune Globulin, Prophylaxis, Telbuvidine, Vaccine August 2012
NCT01788371 Hua Zhang|Icahn School of Medicine at Mount Sinai|Beijing YouAn Hospital Hepatitis B Infection|Chronic Infection|Viremia March 2009 Phase 4
NCT02301650 Beijing Ditan Hospital the Safety of Anti-viral Drugs Used in Late Pregnancy October 2014
NCT01480492 Cz Li|Changhai Hospital HBeAg Positive Chronic Hepatitis B Infection January 2010
NCT02615639 Third Affiliated Hospital, Sun Yat-Sen University|Shanghai Jiao Tong University School of Medicine Chronic Hepatitis B November 2015 Phase 1|Phase 2
NCT00810524 Sun Yat-sen University Hepatitis B, Chronic January 2007 Phase 4
View MoreCollapse
References
Molecular Weight

242.23

Formula

C₁₀H₁₄N₂O₅

CAS No.

3424-98-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.52%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Telbivudine
Cat. No.:
HY-B0017
Quantity: